ArticleZhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences2026
Janus kinase inhibitors enhance the efficacy of dupilumab in refractory atopic dermatitis.
Article in Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectivesPatients with moderate-to-severe atopic dermatitis (AD) often experience intense pruritus and extensive skin lesions, which markedly impair quality of life. Current treatment options, including biologics and small-molecule agents, may provide limited efficacy and are associated with adverse effects. For patients who respond inadequately to dupilumab, particularly those with insufficient control of pruritus, more effective therapeutic strategies are needed. This study aims to evaluate the efficacy, safety, and clinical value of combining dupilumab with Janus kinase inhibitors (JAKis) in the treatment of refractory AD.
methodsThis retrospective study assessed the efficacy and safety of combination therapy with dupilumab and JAKis in 7 patients with refractory moderate-to-severe AD. Patients received either abrocitinib (100 mg/d) or upadacitinib (15 mg/d) in combination with dupilumab. Disease severity before and after combination therapy was evaluated using the Eczema Area and Severity Index (EASI), Scoring Atopic Dermatitis (SCORAD), Patient-Oriented Eczema Measure (POEM), Dermatology Life Quality Index (DLQI), Itch Numerical Rating Scale (Itch-NRS), and Sleep Disorder Numerical Rating Scale (Sleep-NRS). Adverse events were also recorded.
resultsAfter 4 weeks of combination therapy, patients with AD who had shown an inadequate response to dupilumab monotherapy exhibited marked improvement in skin lesions. Significant reductions were observed in EASI, SCORAD, POEM, DLQI, Itch-NRS, and Sleep-NRS scores (all
conclusionsIn patients with AD who show an inadequate response to continued dupilumab treatment, the addition of JAKis can significantly enhance therapeutic efficacy and is generally well tolerated. This combination regimen may represent a promising treatment option for refractory AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.